SVF
Level A· Stronger Clinical EvidenceMeta-analysis

The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.

Ahmed OTF., Ahmed ZT., Dairi AW., Zain Al-Abeden MS., Alkahlot MH., Alkahlot RH.

Meta-analysis with a reported sample of 1184 on Cardiovascular Disease, Stroke Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
1184
PMID
40221807
DOI
10.1186/s13287-025-04209-5

Abstract (original English)

Recent randomized controlled trials have consistently demonstrated the safety and potential efficacy of MSC therapy for heart failure patients. This study delves into mesenchymal stem cells' promising potential, offering a beacon of hope for the future of heart failure treatment with reduced ejection fraction (HFrEF). We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for this systematic review and meta-analysis. We searched four databases and registers for RCTs, including PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other relevant websites. We then selected thirteen RCTs with 1184 participants based on our pre-defined inclusion/exclusion criteria. Two independent assessors extracted the data and performed a quality assessment. The data were then plotted for various outcomes, including death, hospitalization, major adverse cardiac events, pump function parameters, and 6-min walk distance. The safety of MSC-based treatment has been consistently demonstrated with MSCs from autologous ( Auto MSCs) and allogeneic ( Allo MSCs) sources. This reassuring finding underscores the reliability of MSC-based therapy irrespective of their source. However, Auto MSCs showed a trend toward greater protective benefits. Subgroup analysis revealed no significant differences between Auto MSCs and Allo MSCs in improving LVEF; 0.86% (95% CI - 1.21-2.94%) for

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansHeart FailureMesenchymal Stem Cell TransplantationMesenchymal Stem CellsRandomized Controlled Trials as TopicStroke VolumeTransplantation, AutologousTransplantation, Homologous
Systemic / IVCardiovascular DiseaseStroke Research
View on PubMedDOI

Related research